Non-small Cell Lung Cancer Stage III
Conditions
Keywords
Erlotinib, adjuvant therapy, radical operation, IIIA NSCLC, EGFR mutation
Brief summary
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.
Interventions
Sponsors
Roche Pharma AG
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* IIIA NSCLC patients according to TMN-staging of Lung Staging Standard version 7 2009, confirmed by histopathology or cytology after radical operation, and having EGFR exon 19 deletion mutation or exon 21 L858R single base substitution; * Accept study adjuvant therapy within 6 weeks post radical operation; * ECOP PS 0-1; Life expectancy ≥12 weeks; * Hematology: absolute neutrophil count (ANC) ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin concentration ≥ 9.0 g/dL (permit to maintain hematologic criteria by blood transfusion); * Liver Function: TBil ≤1.5xULN; ALT and AST ≤2.5xULN; * Renal Function: Cr ≤1.25xULN, and Ccr ≥60ml/min; * Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days before study treatment; * Signed inform consent form by patient or his/her legal representative; * Comply with study protocol and procedure, and be able to take oral medication; Aged ≥18 years and ≦75 years; * Eligible patients of reproductive potential (both sexes) must agree to use a reliable method of birth control before enrollment, during the study period and for at least 30 days after their last dose of study therapy;
Exclusion criteria
* Having treated by Her-Target therapy, i.e. erlotinib, gefitinib, cetuximab, trastuzumab; * Having treated by any systemic anti-tumor therapy of NSCLC, including cytotoxic therapy, target medication treatment (i.e. monoclonal antibody), investigational therapy; * Having local radiotherapy of NSCLC; Upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer; * The findings in radical operation are lymph nodes with extracapsular invasion, or fusion, or all of dissection lymph nodes positive by pathology; * Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival,cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor); * Confirmed recurrent cancer by Clinical objective evidence (pathology or radiography images) before the study adjuvant therapy; * Known hypersensitivity to platinum, Vinorelbine, EGFR-TKI agents or relevant components in the formulation; * Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection; * Active interstitial lung disease (ILD) by any clinical evidence; patients with any co-morbidities, or motalic disorders, or any abnormal findings in physical examination or laboratory tests are suspected to have contraindication of study therapy or high risk of study treatment complications; * Any unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, angina starting in latest 3 months, Congestive heart failure (NYHA ≥ II), myocardial infarction within 6 months prior enrollment, under medication treatment of severe arrhythmia, liver, renal or metabolic disease; * know HIV infection Pregnant or breastfeeding women; * ECOG PS ≥2; * Mixed with small cell lung cancer; * Other conditions investigators evaluate that patient is not eligible to this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year disease free survival rate (DFSR) | 2 years | 2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disease free survival | 5 years | Disease free survival is defined as the time from randomization to disease recurrence or death which comes first. |
| overall survival (OS) | 5 years | Overall survival is defined as the time from randomization to death. |
| Quality of Life | 5 years | The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS) |
| Adverse Event (AE) | 5 years | frequency of Adverse Event |
| Serious Adverse Event (SAE) | 5 years | Frequency of Serious Adverse Event (SAE) |
Countries
China
Outcome results
None listed